See ratings and reviews when you sign up for an account.

Nasonex? Nasal Suspension 50 ?g Long-term Designated Drug Use Investigation

This study is currently Recruiting

October 2011 By Schering-Plough

First Recieved on May 14, 2009

Last Updated on October 31, 2011

Sponsor: Schering-Plough
Information provided by: Schering-Plough
Identifier: NCT00903721


The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Study Type: Observational
Study Design: Observational Model: Cohort, Time Perspective: Prospective


Ages Eligible for Study:N/A
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis. Exclusion Criteria: - Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection [symptoms may exacerbate] - Patients with a history of hypersensitivity to any ingredient of this drug



  • Coordinating Location

    Osaka, Japan

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.